pharmaphorum

DECEMBER 14, 2022

The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer. They also said they plan to discuss the phase 2b results with regulators.

Vaccine 98

Vaccine Vaccination Trials Gene Sequencing 98

pharmaphorum

JUNE 23, 2022

The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis. billion in potential milestones if the project advances through development and onto the market.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

JANUARY 5, 2023

The data was from their phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – thought to be driving a patient’s cancer. The post Boost for mRNA as Moderna to acquire OriCiro for $85 million appeared first on.

Gene Sequencing 97

Gene Sequencing DNA Vaccine Vaccination 97

pharmaphorum

MARCH 10, 2022

18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials.

Genetics 98

Genetics Gene Sequencing Gene Clinical Trials 98

pharmaphorum

OCTOBER 12, 2022

The neoantigens are selected based on gene sequencing of either a tumour biopsy or a blood sample, with an individual vaccine tailored to the patient manufactured and administered in a matter of weeks.

Vaccine 105

Vaccine Vaccination Gene Sequencing RNA 105

pharmaphorum

SEPTEMBER 14, 2022

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). The current schedule is for trials to start in 2024, with first safety and efficacy data coming a year later.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52

pharmaphorum

MAY 18, 2021

Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available “by early summer.” The purified vaccine is administered alongside GSK’s pandemic adjuvant to boost the immune response.

Vaccine 64

Vaccine Vaccination Immune Response Gene Sequencing 64